




PCT/AU03/01377

0 / 531303


REC'D 17 NOV 2003	
WIPO	PCT

14 APR 2005

Patent Office
Canberra



I, JANENE PEISKER, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. 2002952121 for a patent by ALCHEMIA PTY LTD as filed on 17 October 2002.



WITNESS my hand this
Sixth day of November 2003

JANENE PEISKER
TEAM LEADER EXAMINATION
SUPPORT AND SALES

BEST AVAILABLE COPY

NOVEL CARBOHYDRATE BASED ANTI-BACTERIALS

FIELD OF THE INVENTION

The Invention relates to disaccharides useful as antibacterial agents, methods of screening such compounds for anti-bacterial activity, 5 methods of treatment using such compounds, and pharmaceutical compositions of such compounds

BACKGROUND OF THE INVENTION

Bacteria have a great ability to generate resistance to drugs through lateral gene transfer, mutation of enzymes, or by expressing enzymes 10 which actively pump out the drug or break it down. Over the past 10 years resistance to existing drugs has become a significant problem in many countries. No new antibacterial drugs have been developed over the past 15 years. Vancomycin is currently the drug of last resort to combat the multidrug resistant Gram-positive bacteria. In many places vancomycin-resistant Staphylococcus 15 Aureus and Enterococci (VRE) have been discovered. There is thus a desperate need for a new antibacterial drug to replace the drug of last resort.

There are a host of cytoplasmic targets for the development of new antibacterials, such as gyrase, protein synthesis inhibitors, muramyl cascade inhibitors and many more. The major hurdle in designing such drugs is that in 20 addition to enzyme based activity these drugs need to cross the bacterial cell wall to exert their antibacterial effect. On the other hand, enzymes involved in the stage III synthesis of the bacterial cell wall exist on the cell wall exterior, and therefore drugs inhibiting these enzymes can exert their bactericidal or bacteriostatic effect without having to cross the cell wall. Penicillin, cephalosporin 25 and vancomycin are drugs that act on the transpeptidase enzymes which control the final steps in the peptidoglycan biosynthesis. Moenomycin is known to act on the transglycosylase enzymes, which are similarly involved in the polymerization of disaccharide precursors. Moenomycin displays very high potency at MIC level, and is used in animal feed as a growth promoter.

30 Moenomycin is a lipid-linked pentasaccharide. Through extensive SAR experiments it was realised that smaller fragments of moenomycin were

capable of exerting antibacterial activity. Disaccharide fragments of moenomycin still display antibacterial activity, but are not sufficiently stable to be useful drugs. On the basis of this, Sofia and coworkers discovered a new series of disaccharides, carrying aromatic substituents in well defined positions around the
 5 disaccharide, which displayed significant MIC activity [WO0064915 and WO9926596].

A further class of disaccharide molecules, based on a sub-structure of vancomycin was shown to have antibacterial activity against vancomycin resistant bacteria. This class of molecules was subsequently demonstrated to
 10 contain transglycosylase inhibitors, and were not transpeptidase inhibitors as is vancomycin itself [WO9853813].

SUMMARY OF THE INVENTION


The present invention is directed to carbohydrate compounds and particularly disaccharide like moieties that display antibacterial activity against
 15 Gram-positive bacteria.

The present invention is also directed to method for the treatment of humans or animals using such compounds in a therapeutically effective amount.

The present invention is also directed to pharmaceutical preparations containing such compounds.


20 The present invention is also directed to a method of screening such compounds for anti-bacterial activity by contacting the compounds with a Gram-positive bacteria and monitoring the growth or growth inhibition of the bacteria.

In a first aspect, the invention provides disaccharide compounds of
 25 General Formula I,




General Formula 1

Wherein the pyranose rings may be of any configuration, T is either R or -XR, where X is defined as oxygen, sulphur, NHC(O)-, and wherein R is selected from the non-limiting set comprised of H, or an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1 to 20 atoms which is optionally substituted, and can be branched or linear. Typical substituents include but are not limited to OH, NO, NO₂, NH₂, N₃, halogen, CF₃, CHF₂, CH₂F, nitrile, alkoxy, aryloxy, amidine, guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramidate, hydrazide, hydroxamate, hydroxamic acid, heteroaryloxy, aminoalkyl, aminoaryl, aminoheteroaryl, thioalkyl, thioaryl or thioheteroaryl, which may optionally be further substituted, U and Z independently selected from OR, NHR, NHR(R) (where R may be the same or different), or the following non-limiting set,




20 R¹ and R² are independently selected from H, CH₃, CH₂XR, and C(O)NHR, R³ and R⁴ are independently selected from H, OH, OR, NHCOR, and W is independently selected from OR^L, NHR^L, NR^LR, or the following the following non-limiting set.



Wherein R^L is a substituted or unsubstituted, linear or branched, saturated or unsaturated C3 to C55 alkyl, heteroalkyl, arylalkyl, alkylaryl chain. Substituents may include but are not limited to acidic groups such as carboxylic acids, sulfonic acids, phosphoric acids, tetrazoles, or other carboxylic acid mimetics.


In one embodiment the invention provides disaccharide compounds of General Formula II,



General Formula II

Wherein the disaccharide linkage is alpha or beta, A is defined as hydrogen, OR or SR, and R, U, W, Z and R^4 are defined as in General Formula I.

In a more preferred embodiment, the invention provides disaccharide compounds of General Formula III,



5


General Formula III

Wherein A is defined as in General Formula I, and U, Z, R^L and R⁴ are defined as in General Formula I.

In a second aspect, the invention provides a method of treatment of a bacterial infection, comprising the step of administering an effective amount of a compound of the first aspect, to a subject in need of such treatment. The subject may be a human, or may be a domestic, companion or zoo animal.


Methods and pharmaceutical carriers for preparation of pharmaceutical compositions are well known in the art, as set out in textbooks such as Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Company, Easton, Pennsylvania, USA.

Example 1: Synthesis of 1-deoxy-1-H-2,4-deoxy-2,4-N-Galactosyl Acceptor




- 5 **Conditions:** (i) Bu_3SnH , toluene, reflux, 2.5hrs, quant.; (ii) NaOMe/MeOH , 2hrs, RT, quant.; (iii) *p*-methoxybenzaldehyde dimethylacetal, *p*-toluenesulphonic acid, DMF, 6hrs, 70°C , 86%; (iv) *p*-chlorobenzoylchloride, pyridine, 1hr, RT, 83%; (v) NaCNBH_3 , TFA, Mol. sieves 3\AA , DMF, 16hrs, 55°C , 93%; (vi) (a) Tf_2O , pyridine, DCM, -20°C , (b) NaN_3 , DMF, 1hr, RT, 93%; (vii) NaOMe/MeOH , RT, quant.; (viii) hydrazine, butanol; (ix) (a) Phthalic anhydride, methanol, (b) Ac_2O , pyridine; (x) NaOMe/MeOH .
- 10


Example 2: Synthesis of 2-deoxy-2-*N*-Glucopyranoside Donors



Conditions: (i) NaH, 4-MeOBnCl; (ii) (a) DTT, TEA (b) BzCl, DIPEA; (iii) (a) NBS, (b) Cl₃CN, DBU; (iv) (a) NBS, (b) DTT, TEA; (v) (a) Trifluoroacetic anhydride, (b) NaHCO₃; (vi) Cl₃CN, DBU.

Example 3: Formation of a Disaccharide

Conditions: (i) TMSOTf, DCE; (ii) hydrazine, heat; (iii) Fmoc-Cl, DCE, DIPEA; (iv) (a) ArNCO, or (b) ArC(O)-Cl; (v) piperidine, chloroform; (vi) (a) ArNCO, or (b) ArC(O)-Cl; (vii) DMF, Methanol, ammonium chloride, zinc; (viii) R-CO₂H, HBTU, DIPEA, DMF.

Table 1: Library of Compounds Synthesized

Comp. No	R ¹	R ²
1	A1	A1
2	A1	A2
3	A1	A3
4	A4	A4
5	A5	A6
6	A5	A5
7	A7	A7
8	A4	A2
9	A5	A2
10	A5	A3
11	A7	A6
12	A4	A3
13	A7	A2








**A1****A2****A3****A4****A5****A6****A7**

Table 2: Assay Results After Incubation for 20 Hours.

Compound	Assay 1	Assay 2	Assay 3	Assay 4	Assay 5
Tetracycline	complete inhibition	complete inhibition	complete inhibition	complete inhibition	no inhibition
Tetracycline	complete inhibition	complete inhibition	complete inhibition	complete inhibition	no inhibition
Amphotericin B	no inhibition	no inhibition	no inhibition	no inhibition	complete inhibition
Amphotericin B	no inhibition	no inhibition	no inhibition	no inhibition	complete inhibition
1	-	-	-	-	-
2	-	+	-	-	-
3	-	++	-	-	-
4	-	++	-	-	+
5	-	+	-	-	-
6	-	++	-	-	-
7	-	+	-	-	-
8	-	+	-	-	-
9	-	-	-	-	-
10	-	-	-	-	-
11	-	-	-	-	-
12	-	-	-	-	-
13	-	-	-	-	-

KEY**Assay 1: *Escherichia coli* (Gram Negative)****Assay 2: *Staphylococcus aureus* (Gram Positive)****Assay 3: *Klebsiella pneumoniae* (Gram Negative)****Assay 4: *Pseudomonas aeruginosa* (Gram Negative)****Assay 5: *Candida albicans* Eukaryotic Yeast****All compound test concentrations were at 250 μ M**

"++" indicates an inhibition of greater than 90%

"+" indicates inhibition at greater than 70%

"-" indicates less than 70% inhibition

Table 3: Assay Results After Incubation for 44 Hours.

Compound	Assay 1	Assay 2	Assay 3	Assay 4	Assay 5
Tetracycline	complete inhibition	complete inhibition	complete inhibition	complete inhibition	no inhibition
Tetracycline	complete inhibition	complete inhibition	complete inhibition	complete inhibition	no inhibition
Amphotericin B	no inhibition	no inhibition	no inhibition	no inhibition	complete inhibition
Amphotericin B	no inhibition	no inhibition	no inhibition	no inhibition	complete inhibition
1	-	-	-	-	-
2	-	-	-	-	-
3	-	++	-	-	-
4	-	++	-	-	-
5	-	-	-	-	-
6	-	++	-	-	-
7	-	+	-	-	-
8	-	-	-	-	-
9	-	-	-	-	-
10	-	-	-	-	-
11	-	-	-	-	-
12	-	-	-	-	-
13	-	-	-	-	-

KEY as for Table 2.

Table 4: Selected *In Vitro* Toxicity Data

Compound	Line 1	Line 2	Line 3
3	**	**	*
4	*	**	**
7	**	**	**
13	**	*	*

Line 1: 3T3, mouse embryonic cell line

Line 2: Jurkat, human leukaemia T-cells

Line 3: MCF-7, human breast adenocarcinoma

** indicates no growth inhibition; *** indicates growth inhibition of less than 20%.

Compounds were tested at a concentration of 25µM

It should be appreciated that various other changes and modifications can be made to the embodiments without departing from the spirit and scope of the invention.

Dated this 17th day of October 2002

Alchemia Pty Ltd

By their Patent Attorneys

CULLEN & CO.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.